Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

P.P.M.M. Geusens, W.F. Lems

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)
Original languageEnglish
Pages (from-to)337-344
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number2
Publication statusPublished - 2008

Cite this